Browsing: Pfizer

With global bond yields high and borrowing costs less forgiving, capital is flowing toward companies that can raise productivity rather than just cut expenses. Transformative AI healthcare stocks sit right in that sweet spot. They use data and algorithms to help doctors work faster and more accurately, which can appeal when every dollar needs to…

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business…

Pfizer has halted a trial of an obesity drug that applied D&D Pharmatech’s (347850) oral peptide platform “Oralink.”

S&P 500LLYNVOAMGNPFEMRK 10 min read | July 27, 2026 02:20 PM PDT | By Anmol Khazanchi Google News:

D&D Pharmatech (347850.KQ) has expanded its joint research collaboration with U.S. pharmaceutical company Pfizer on an obesity treatment. Following an additional order from Pfizer, the value of the research service contract has increased 38% from the previous level, and the contract term has been extended until 2028

Humans are very bad at taking medications. By some estimates, adherence to long-term chronic medication treatment plans is only around 50%. This is a big issue for GLP-1 weight-loss drugs, which must be taken for life and as often as daily. Pfizer (NYSE: PFE) is betting that making a more convenient option will give it…